Marubeni Ventures, Inc. (“Marubeni Ventures”) has invested in LPIXEL Inc. (“LPIXEL”), a company specializing in AI-powered diagnostic imaging support (Headquarters: Chiyoda-ku, Tokyo; President & CEO: Tomy Kamada).

LPIXEL develops and provides the “EIRL” series, an AI-based diagnostic imaging support solution targeting major diseases such as lung cancer and colorectal cancer, which are among the leading causes of death. The EIRL series analyzes medical images—captured by X-ray, CT, or MRI devices—using AI to assist physicians in their diagnoses. As of June 2025, the EIRL series has been installed in over 1,000 medical facilities, primarily in Japan, with the total number of analyses exceeding 12 million cases. In addition, LPIXEL offers “IMACEL,” a platform that supports various image analyses in the life sciences field, including pathology specimens and laboratory animals.

Marubeni Ventures will leverage the knowledge and network of the Marubeni Group to support LPIXEL’s business expansion.

LPIXEL
Headquarter : Chiyoda-ku, Tokyo
President & CEO : Tomy Kamada
To view in a PDF format, please click here.